Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 3
2014 2
2015 2
2016 2
2017 1
2019 1
2020 2
2021 1
2022 5
2023 6
2024 6
2025 6
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. O'Donnell PH, et al. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. doi: 10.1200/JCO.22.02887. Epub 2023 Jun 27. J Clin Oncol. 2023. PMID: 37369081 Free PMC article. Clinical Trial.
Here, we present data from the pivotal trial of EV plus Pembro (EV + Pembro) in the 1L setting. PATIENTS AND METHODS: In Cohort K of the EV-103 phase Ib/II study, cisplatin-ineligible patients with previously untreated la/mUC were randomly assigned 1:1 to receive EV as mon …
Here, we present data from the pivotal trial of EV plus Pembro (EV + Pembro) in the 1L setting. PATIENTS AND METHODS: In Cohort K of …
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Jurida G, Kouros-Mehr H, Janát-Amsbury MM, Eggert T, Tran B. Dorff T, et al. Clin Cancer Res. 2024 Apr 15;30(8):1488-1500. doi: 10.1158/1078-0432.CCR-23-2978. Clin Cancer Res. 2024. PMID: 38300720 Free PMC article. Clinical Trial.
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
McKay RR, Pal S, Xie W, Aggen D, Albiges L, Apolo A, Atkins MB, Bangs R, Beckermann KE, Bellmunt J, Berg SA, Bilen MA, Braun D, Carlo MI, Efstathiou J, Galsky M, Grivas P, Gupta S, Haas N, Hakimi AA, Hammers H, Heng DYC, Hirsch M, Iyer G, Jonasch E, Koshkin VS, Kryvenko O, Lewis B, Li R, Matin S, Maughan B, McDermott DF, McGregor B, Meeks J, Milowsky M, Motzer R, Necchi A, Petrylak D, Porten S, Powles T, Rini B, Shuch B, Siefker-Radtke A, Sonpavde G, Sridhar SS, Suarez C, Tang C, Tripathi A, Van Der Heijden MS, Voss M, Xu W, Zhang T, Rosenberg J, Choueiri TK. McKay RR, et al. CA Cancer J Clin. 2026 Jan-Feb;76(1):e70052. doi: 10.3322/caac.70052. CA Cancer J Clin. 2026. PMID: 41389316 Free PMC article.
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
Purdue MP, Dutta D, Machiela MJ, Gorman BR, Winter T, Okuhara D, Cleland S, Ferreiro-Iglesias A, Scheet P, Liu A, Wu C, Antwi SO, Larkin J, Zequi SC, Sun M, Hikino K, Hajiran A, Lawson KA, Cárcano F, Blanchet O, Shuch B, Nepple KG, Margue G, Sundi D, Diver WR, Folgueira MAAK, van Bokhoven A, Neffa F, Brown KM, Hofmann JN, Rhee J, Yeager M, Cole NR, Hicks BD, Manning MR, Hutchinson AA, Rothman N, Huang WY, Linehan WM, Lori A, Ferragu M, Zidane-Marinnes M, Serrano SV, Magnabosco WJ; BioBank Japan Project; Vilas A, Decia R, Carusso F, Graham LS, Anderson K, Bilen MA, Arciero C, Pellegrin I, Ricard S; FinnGen; Scelo G, Banks RE, Vasudev NS, Soomro N, Stewart GD, Adeyoju A, Bromage S, Hrouda D, Gibbons N, Patel P, Sullivan M, Protheroe A, Nugent FI, Fournier MJ, Zhang X, Martin LJ, Komisarenko M, Eisen T, Cunningham SA, Connolly DC, Uzzo RG, Zaridze D, Mukeria A, Holcatova I, Hornakova A, Foretova L, Janout V, Mates D, Jinga V, Rascu S, Mijuskovic M, Savic S, Milosavljevic S, Gaborieau V, Abedi-Ardekani B, McKay J, Johansson M, Phouthavongsy L, Hayman L, Li J, Lungu I, Bezerra SM, Souza AG, Sares CTG, Reis RB, Gallucci FP, Cordeiro MD, Pomerantz M, Lee GM, Freedman ML, Jeong A, Greenbe… See abstract for full author list ➔ Purdue MP, et al. Nat Genet. 2024 May;56(5):809-818. doi: 10.1038/s41588-024-01725-7. Epub 2024 Apr 26. Nat Genet. 2024. PMID: 38671320 Free PMC article.
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.
Mann JFE, Marx N, Deanfield JE, Emerson SS, Inzucchi SE, McGuire DK, Mulvagh SL, Pop-Busui R, Poulter NR, Engelmann MDM, Hovingh GK, Belmar N, Idorn T, Jeppesen OK, Birkenfeld AL, Amod A, Mankovsky B, Desouza C, Gorgojo-Martinez JJ, Arechavaleta R, Tu ST, Buse JB; SOUL Study Group*. Mann JFE, et al. Diabetes Care. 2026 Feb 1;49(2):257-265. doi: 10.2337/dc25-1080. Diabetes Care. 2026. PMID: 41380027 Free PMC article. Clinical Trial.
Executive dysfunction accompanying essential tremor.
Dogan H, Bilen S, Ergin Beton O. Dogan H, et al. Appl Neuropsychol Adult. 2024 Mar-Apr;31(2):128-133. doi: 10.1080/23279095.2021.2002865. Epub 2021 Dec 7. Appl Neuropsychol Adult. 2024. PMID: 34874215
Both patients and control group were subjected to the Mini Mental Test, followed by the Stroop TBAG test (TBAG is composed of the first letters of "TUBITAK Temel Bilimler Arastirma Grubu," which means Scientific and Technological Research Council of Turkey Basic Sciences Research …
Both patients and control group were subjected to the Mini Mental Test, followed by the Stroop TBAG test (TBAG is composed of the first lett …
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.
Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Nizam A, et al. Cancer Med. 2025 Oct;14(19):e71284. doi: 10.1002/cam4.71284. Cancer Med. 2025. PMID: 41031719 Free PMC article.
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O. Jiang CY, et al. Oncologist. 2025 Nov 11;30(11):oyaf342. doi: 10.1093/oncolo/oyaf342. Oncologist. 2025. PMID: 41056445 Free PMC article.
35 results